# IMPAKT CONFERENCE PROGRAMME

## Thursday, 8 May 2014

### 13:00 - 13:15
**Official welcome**

**GOLD HALL**

- 13:00 Welcome to the IMPAKT Conference
  Martine Piccart, Brussels, Belgium

- 13:05 Scientific Introduction to the IMPAKT Conference
  Giuseppe Curigliano, Milan, Italy and Alastair M. Thompson, Houston, TX, US

### 13:15 - 14:00
**Opening Keynote lecture**

**GOLD HALL**

- 13:15 Patient-derived tumour xenografts as models for breast cancer drug development
  Mike T. Lewis, Houston, TX, US

- 13:45 Q&A

### 14:00 - 15:30
**Xenopatients and mouse models to predict drug sensitivity and resistance in breast cancer**

**GOLD HALL**

- 14:00 Understanding the determinants of drug sensitivity and resistance in mouse models of human HER 2 positive breast cancer
  Kent Osborne, Houston, TX, US

- 14:20 Modelling of response to treatment in human breast cancer xenografts
  Elisabetta Marangoni, Paris, France

- 14:40 Empirical tumourgraft testing and deep sequencing data in patient care
  Charles M. Perou, Chapel Hill, NC, US

- 15:00 Clinical perspectives and debate: Xenograft models of solid tumours: Problems, pitfalls and future directions
  Pro Speaker: Geoff Lindeman, Parkville, Australia
  Contra Speaker: Angelo Di Leo, Prato, Italy

- 15:20 Q&A / General discussion

### 15:30
Coffee break
16:00/ 17:30 Best abstracts session - Oral presentations  
Chairs: Giuseppe Curigliano, Milan, Italy and Alastair M. Thompson, Houston, TX, US

16:00 120 - Molecular subtype of breast cancer metastases significantly influences patient post-relapse survival
Nicholas Tobin, Stockholm, Sweden

16:10 130 - Evolutionary patterns of microRNA expression through the course of disease and therapy in recurrent breast cancer
Maya Dadiani, Ramat Gan, Israel

16:20 200 - Analysis of molecular scores for the prediction of distant recurrence according to body mass index and age at baseline
Ivana Sestak, London, UK

16:30 210 - A novel methylation signature that reflects intratumoral lymphocyte infiltration in breast cancer and predicts for response to anthracycline treatment
Jana Jeschke, Brussels, Belgium

16:40 Discussant Abstracts 120, 130, 200 and 210
Peter Dubsky, Vienna, Austria

16:55 590 - Targeting CDK4/6 in Her2 positive breast cancer: Therapeutic effect, markers, and combination strategies
Erik Knudsen, Dallas, TX, US

17:05 650 - Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer (BC)
Carmen Criscitiello, Naples, Italy

17:15 Discussant Abstracts 590 and 650
Nicholas Turner, London, UK

17:30 Welcome reception and Poster Walk
See page 30 for details
Friday, 09 May 2014

08:30/  Keynote lecture
09:15  Chairs: Alberto Bardelli, Candiolo, Italy and Kent Osborne, Houston, TX, US
08:30  Liquid biopsies to monitor response and resistance to targeted therapies
Alberto Bardelli, Candiolo, Italy
09:00  Q&A

09:15/  Liquid biopsies: Genotyping circulating tumour DNA in breast cancer
10:30  Chairs: Fabrice André, Villejuif, France and Daniel F. Hayes, Ann Arbor, MI, US
09:15  Circulating exosomes and microRNAs
Salvatore Pece, Milan, Italy
09:35  Circulating tumour cells: Isolation, enrichment and clinical value
Michail Ignatiadis, Brussels, Belgium
09:55  Clinical perspectives and debate:
Liquid biopsies for genotyping and monitoring breast cancer: Ready for prime time?
Pro Speaker: Daniel F. Hayes, Ann Arbor, MI, US
Contra Speaker: Mitchell Dowsett, London, UK
10:15  Q&A / General discussion
10:30  Coffee break

11:00/  Ethical and legal barriers to large molecular sequencing projects
12:15  Chairs: Lisa A. Carey, Chapel Hill, NC, US and Lucy Connolly, Hinxton, UK
11:00  Overcoming operational challenges of personalised cancer therapy
Fraser Symmans, Houston, TX, US
11:15  Consent forms in genomics: Assessing the privacy risks of data sharing
Katherine Nathanson, Philadelphia, PA, US
11:30  Ethical, legal and social implications of the use of whole genome methods in medical research
Harriet Teare, Oxford, UK
11:45  Visualising the true spectrum of cancer by molecular sequencing: Will we get convergence from divergence?
Lucy Connolly, Hinxton, UK
12:00  Q&A / General discussion
12:15/ INDUSTRY SATELLITE SYMPOSIUM     SILVER HALL
13:15 Exploring biomarkers of efficacy and resistance in estrogen receptor–positive and HER2-positive advanced breast cancer: Let’s make it personal
See page 39 for details

13:15 Lunch

13:45/ INDUSTRY SATELLITE SYMPOSIUM     GOLD HALL
15:15 From biology to oncology: Targeting ER+/HER2– breast cancer
See page 39 for details

15:15 Coffee break

15:30/ Keynote Lecture     GOLD HALL
16:15 Chairs: Fabrice André, Villejuif, France and Karen Willard-Gallo, Brussels, Belgium
15:30 Defining critical hurdles in cancer immunotherapies
George Coukos, Lausanne, Switzerland
16:00 Clinical implications of immune modulation in breast cancer
Fabrice André, Villejuif, France

16:15/ Biomathematics in the development of personalised medicine in oncology     GOLD HALL
17:45 Chairs: Mark Chaplain, Dundee, UK and Alastair M.Thompson, Houston, TX, US
16:15 Calibrating breast cancer simulations with patient pathology: Progress and future steps
Paul Macklin, Los Angeles, LA, US
16:35 Mathematical modelling of cancer from cell to tissue level
Mark Chaplain, Dundee, UK
16:55 High dimensional biomarkers as treatment modifiers in randomised clinical trials
Stefan Michiels, Villejuif, France
17:15 Clinical perspectives
Alastair M.Thompson, Houston, TX, US
17:30 Q&A / General discussion

17:45/ How can international collaboration benefit young researchers?     GOLD HALL
18:30 Panellists: Fabrice André, Villejuif, France; Giuseppe Curigliano, Milan, Italy; Evandro De Azambuja, Brussels, Belgium; Carsten Denkert, Berlin, Germany; Phuong Dinh, Sydney, Australia; Peter Dubsky, Vienna, Austria; Sibylle Loibl, Neu-Isenburg, Germany; Alastair M. Thompson, Houston, TX, US
Early-career breast cancer specialists will share their own experience with international collaboration: What have been the benefits, but also the challenges of working on international, collaborative research efforts? How did they get involved with such projects? Panellists will be available to answer questions.
Debate: Should prognostic genomic tests be “routinely” used in clinical practice?
Updates and news since the 2012 edition
Chairs: Christos Sotiriou, Brussels, Belgium and Fraser Symmans, Houston, TX, US

Updates and news since the 2012 edition
Fraser Symmans, Houston, TX, US

Utility of prognostic genomic tests in breast cancer practice: IMPAKT international expert opinion for utility of prognostic genomic tests in breast cancer practice
Panellists: Hatem A. Azim Jr., Brussels, Belgium; Fabrice André, Villejuif, France; Giuseppe Curigliano, Milan, Italy; Angelo Di Leo, Prato, Italy; Christine Desmedt, Brussels, Belgium; Mitchell Dowsett, London, UK; Peter Dubsky, Vienna, Austria; Daniel F. Hayes, Ann Arbor, MI, US; Stefan Michiels, Villejuif, France; Kent Osborne, Houston, TX, US; Charles M. Perou, Chapel Hill, NC, US; Martine Piccart, Brussels, Belgium; Jorge Reis-Filho, New York, NY, US; Christos Sotiriou, Brussels, Belgium; Charles Swanton, London, UK; Alastair M. Thompson, Houston, TX, US; Nicholas Turner, London, UK; Andrew Tutt, London, UK and Giuseppe Viale, Milan, Italy

Coffee break

Susan G. Komen for the Cure® award session

New drugs and trials on the horizon
Chairs: Mitchell Dowsett, London, UK and Peter Dubsky, Vienna, Austria

Personalised medicine in breast cancer: Where have we come from and where are we going?
Fabrice André, Villejuif, France

The AURORA initiative for advanced breast cancer
Martine Piccart, Brussels, Belgium

Whole-genome sequencing and cancer therapy: What is too much?
Jorge Reis-Filho, New York, NY, US

“Genome-Forward” trials
Lisa A. Carey, Chapel Hill, NC, US

Targeting the CDK4/6 pathways
Luca Malorni, Prato, Italy

Q&A / General discussion

Closing remarks and introduction of the IMPAKT 2015 Chairs
Giuseppe Curigliano, Milan, Italy and Alastair M. Thompson, Houston, TX, US